Accessibility Menu
ETHZilla logo

ETHZilla(NASDAQ) ATNF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-81%
1 Month+6%
N/A
ETHZilla last closing stock price
MetricPriceDate
Last closeUSD 5.662026-08-27
ETHZilla stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.25%USD 5.852026-08-20
1 month+6.39%USD 5.322026-07-28
3 month+27.77%USD 4.432026-05-29
Year to date+15.51%USD 4.902025-12-31
1 year-81.01%USD 29.802025-08-27
3 year-94.66%USD 106.022023-08-28
5 year-99.97%USD 19,836.002021-08-27
Since inception-99.98%USD 36,859.992017-06-27

ETHZilla Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.45B

Net Income (TTM)

-$450.61B

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 11, 2025

ATNF News

physician-at-work-getty

Why 180 Life Sciences Stock Is Falling Today

Cory RenauerAug 19, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ETHZilla

180 Life Sciences Corp. is a biotechnology company focused on researching and developing innovative therapies for inflammatory diseases. The company targets significant unmet medical needs with its main focus on anti-TNF (tumor necrosis factor) biologics, addressing conditions like Dupuytren’s contracture and frozen shoulder. Led by a team with extensive pharmaceutical expertise, 180 Life Sciences aims to advance its pipeline through clinical trials, strategic partnerships, and licensing opportunities.

Products and Services

Anti-TNF biologics targeting inflammatory diseases

Research and development of therapies for Dupuytren’s contracture

Treatment development for frozen shoulder

Expanding pipeline of novel therapeutics

What Makes 180 Life Sciences Corp. Special

180 Life Sciences Corp. distinguishes itself through its focus on unique anti-TNF biologics, which target specific inflammatory pathways. This innovative approach could reshape treatment paradigms in its target conditions, setting it apart in the biotech industry. Its experienced leadership enhances its capabilities in development and commercialization strategies.

Five Things You Need to Know

The company focuses on unmet medical needs in the inflammatory disease sector.

Its leadership comprises seasoned pharmaceutical veterans.

The anti-TNF biologics target specific inflammatory pathways, unlike traditional therapies.

Strategic growth involves clinical trials and development partnerships.

180 Life Sciences is built on leveraging intellectual property for licensing opportunities.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

McAndrew A. Rudisill

Website

www.ethzilla.com

Headquarters

Palo Alto, CA 94306, US

ATNF Financials

Key Financial Metrics (TTM)

Gross Margin

82.33%

Operating Margin

-2366.40%

Net Income Margin

-4896.82%

Return on Equity

-215.13%

Return on Capital

-47.60%

Return on Assets

-331.66%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$398.00K

Operating Income

-$243.92M

EBITDA

-$9.82B

Operating Cash Flow

-$25.32B

Capital Expenditure

-$16.81M

Free Cash Flow

-$25.34B

Cash & ST Invst.

$4.10M

Total Debt

$0.00

ETHZilla Performance Analysis

ETHZilla annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 6,547,000N/A
ETHZilla sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3159192.0%
Q12026-03-31-99.9%
Q22026-06-30-52.3%
ETHZilla annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3,871.8257.2%
20232023-12-31USD -525.87-86.4%
20242024-12-31USD -154.91-70.5%
20252025-12-31USD -55.18-64.4%
ETHZilla sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5716.7%
Q42025-12-31-68943.0%
Q12026-03-31100.0%
Q22026-06-3097.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.37M

N/A

Gross Profit

$398.00K

N/A

Gross Margin

29.16%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

4

N/A

Net Income

-$12.82M

-642.4%

EBITDA

-$9.94M

-474.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.10M

+84.9%

Total Debt

$0.00

-100.0%

Accounts Receivable

$18.23M

+168993.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.32%

N/A

Return on Invested Capital

-1.66%

N/A

Free Cash Flow

-$12.11M

-970.5%

Operating Cash Flow

-$12.11M

-970.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADTXAditxt, Inc.
$0.01+8.70%
BXRXQBaudax Bio, Inc.
$0.00+0.00%
ENSCEnsysce Biosciences, Inc.
$0.40-3.16%
MTVAMetaVia Inc.
$1.66-1.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$227.98+0.09%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$45.35-0.06%
IRENIren
$40.53+0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$123.05+0.06%

Questions About ATNF

What is the current price of ETHZilla?

ETHZilla is trading at N/A per share.

What is the 52-week range for ETHZilla?

Over the past 52 weeks, ETHZilla has traded between N/A and N/A.

How much debt does ETHZilla have?

As of the most recent reporting period, ETHZilla reported total debt of $25.95M.

How much cash does ETHZilla have on hand?

ETHZilla reported $4.10M in cash and cash equivalents in its most recent financial results.

What is ETHZilla’s dividend yield?

ETHZilla does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services